|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||30.10 / 67.10|
Event Scheduled for Monday, March 12, 2018 at 12:30 p.m. ET
Company to Host Conference Call on Tuesday, February 20, 2018, at 5:00 p.m. ET
The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 553,785 share increase in total short interest for Portola Pharmaceuticals, Inc. , to 4,455,929, an increase of 14.19% since 12/29/2017.
Bevyxxa Available to Patients in January 2018
The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).
Portola and WTD Aim to Make VTE Protocol and Prevention a Priority Patient Safety Issue in Hospitals Across the United States
Jim Cramer is bullish on Southwest, Delta, General Electric, and Portola Pharmaceuticals.
From Apple's orders and funds liquidating winners to the slow-growing cloud narrative, Jim Cramer explains why he thinks this is selloff is really an opportunity.
The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Portola Pharmaceuticals, Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.